All In Biotech

Drug Trial Radar · NCT06441227

Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects

Phase I Clinical Study on the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Food Effects of Single and Multiple Oral HRS-5346 Tablets in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

71

Actual

Start

Jun 13, 2024

Primary completion

Jan 9, 2025

Study completion Jan 9, 2025

Sponsor

Sponsor type
Industry
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled phase I clinical study. The primary objective is to evaluate the safety, tolerability, PK, and PD of single- and multiple-dose HRS-5346 in healthy subjects, and to evaluate the food effects on PK of HRS-5346.

Conditions

  • Lipoprotein Disorder Disease

Interventions

  • HRS-5346 tabletsDrug

    Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.

  • placeboDrug

    Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the incidence and severity of adverse events in healthy subjects after single and multiple doses of HRS-5346 tabletsTime frame: About three months from the first medication to the evaluation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Suzhou University

    Suzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.